![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Fischer, Luca 
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
ORCID: https://orcid.org/0000-0003-2444-416X; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Schmidt, Christian; Stilgenbauer, Stephan ORCID: https://orcid.org/0000-0002-6830-9296; Bouabdallah, Krimo; Solal-Celigny, Philippe; Scholz, Christian W.; Feugier, Pierre; Wit, Maike de; Trappe, Ralf Ulrich; Hallek, Michael; Graeven, Ullrich ORCID: https://orcid.org/0000-0001-6082-7710; Hänel, Mathias; Hoffmann, Martin; Delwail, Vincent; Macro, Margaret; Greiner, Jochen ORCID: https://orcid.org/0000-0003-1256-173X; Giagounidis, Aristoteles A. N.; Dargel, Beate; Durot, Eric ORCID: https://orcid.org/0000-0003-3463-0089; Foussard, Charles; Silkenstedt, Elisabeth; Weigert, Oliver ORCID: https://orcid.org/0000-0002-0987-7373; Pott, Christiane ORCID: https://orcid.org/0009-0005-9260-8340; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389; Ribrag, Vincent und Dreyling, Martin
(2024):
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network.
In: Leukemia, Bd. 38: S. 1307-1314
[PDF, 1MB]
Hermine, Olivier ORCID: https://orcid.org/0000-0003-2574-3874; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Walewski, Jan ORCID: https://orcid.org/0000-0003-4247-2674; Bosly, André; Thieblemont, Catherine ORCID: https://orcid.org/0000-0002-9941-2448; Szymczyk, Michal; Pott, Christiane; Salles, Gilles ORCID: https://orcid.org/0000-0002-9541-8666; Feugier, Pierre; Hübel, Kai; Haioun, Corinne; Casasnovas, René Olivier ORCID: https://orcid.org/0000-0002-1156-8983; Schmidt, Christian; Bouabdallah, Kamal; Ribrag, Vincent; Kanz, Lothar; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Metzner, Bernd; Sibon, David ORCID: https://orcid.org/0000-0002-9205-625X; Cheminant, Morgane; Burroni, Barbara; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2022):
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma. Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
In: Journal of Clinical Oncology, Bd. 41, Nr. 3: S. 479-484
ORCID: https://orcid.org/0000-0003-2574-3874; Jiang, Linmiao ORCID: https://orcid.org/0000-0002-9009-4236; Walewski, Jan ORCID: https://orcid.org/0000-0003-4247-2674; Bosly, André; Thieblemont, Catherine ORCID: https://orcid.org/0000-0002-9941-2448; Szymczyk, Michal; Pott, Christiane; Salles, Gilles ORCID: https://orcid.org/0000-0002-9541-8666; Feugier, Pierre; Hübel, Kai; Haioun, Corinne; Casasnovas, René Olivier ORCID: https://orcid.org/0000-0002-1156-8983; Schmidt, Christian; Bouabdallah, Kamal; Ribrag, Vincent; Kanz, Lothar; Dürig, Jan ORCID: https://orcid.org/0000-0002-7672-3905; Metzner, Bernd; Sibon, David ORCID: https://orcid.org/0000-0002-9205-625X; Cheminant, Morgane; Burroni, Barbara; Klapper, Wolfram; Hiddemann, Wolfgang; Unterhalt, Michael; Hoster, Eva ORCID: https://orcid.org/0000-0002-0749-1389 und Dreyling, Martin ORCID: https://orcid.org/0000-0002-0358-5249
(2022):
High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma. Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
In: Journal of Clinical Oncology, Bd. 41, Nr. 3: S. 479-484
Hiddemann, Wolfgang; Barbui, Anna Maria; Canales, Miguel A.; Cannell, Paul K.; Collins, Graham P.; Dürig, Jan; Forstpointner, Roswitha; Herold, Michael; Hertzberg, Mark; Klanova, Magdalena; Radford, John; Seymour, John F.; Tobinai, Kensei; Trotman, Judith; Burciu, Alis; Fingerle-Rowson, Günter; Wolbers, Marcel; Nielsen, Tina und Marcus, Robert E.
(2018):
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
In: Journal of Clinical Oncology, Bd. 36, Nr. 23: S. 2395-2404
[PDF, 904kB]
Wendtner, Clemens M.; Hallek, Michael; Fraser, Graeme A. M.; Michallet, Anne-Sophie; Hillmen, Peter; Dürig, Jan; Kalaycio, Matt; Gribben, John G.; Stilgenbauer, Stephan; Buhler, Andreas; Kipps, Thomas J.; Purse, Brendan; Zhang, Jennie; De Bedout, Sabine; Mei, Jay und Chanan-Khan, Asher
(2016):
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*.
In: Leukemia & Lymphoma, Bd. 57, Nr. 6: S. 1291-1299